Teva Acquires Ratiopharm for $4.9B | co2 Tax

Teva Acquires Ratiopharm for $4.9B

generic markets such as Spain, Italy and France.' The price tag for Ratiopharm reflects an earnings before interest, taxes, depreciation and amortization (EBITDA) multiple of 11.4 and a sales multiple of 2.2, based on Ratiopharm's figures for 2009. For

This entry is filed under General, environmental tax, environmental tax credit, environmental tax incentives, environmental tax reform. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.